Structure and chemical inhibition of the RET tyrosine kinase domain - Wikidata - awgldk - TriplyDB

Structure and chemical inhibition of the RET tyrosine kinase domain

Structure and chemical inhibition of the RET tyrosine kinase domain

http://www.wikidata.org/entity/Q28259608

about

Structural basis for the recognition of c-Src by its inactivator Csk Cell signaling by receptor tyrosine kinases Targeting cancer with kinase inhibitors The Structure of the Glial Cell Line-derived Neurotrophic Factor-Coreceptor Complex: INSIGHTS INTO RET SIGNALING AND HEPARIN BINDING A crystallographic snapshot of tyrosine trans-phosphorylation in action Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated Schwannomas Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase Sequence and structure signatures of cancer mutation hotspots in protein kinases Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update Zebrafish GDNF and its co-receptor GFRα1 activate the human RET receptor and promote the survival of dopaminergic neurons in vitro Cancer driver mutations in protein kinase genes Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases.Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein Role of vandetanib in the management of medullary thyroid cancer Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.Structural and mechanistic insights into the bifunctional enzyme isocitrate dehydrogenase kinase/phosphatase AceK.Heterozygous p.S811F RET gene mutation associated with renal agenesis, oligomeganephronia and total colonic aganglionosis: a case report.Contactin 1 as a potential biomarker promotes cell proliferation and invasion in thyroid cancer Cancer genes in lung cancer: racial disparities: are there any?Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies.Structure and physiology of the RET receptor tyrosine kinase.Receptor tyrosine kinases: mechanisms of activation and signaling.Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.New drugs in thyroid cancer.Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases.High-throughput kinase profiling as a platform for drug discovery.Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.

P2860

Q24311447-1A2B64A6-E3A6-4B29-88FF-039E9FD014CA Q24598357-C85B184A-4CB8-4CC9-B10D-E04A33BCDD06 Q26865765-58C25D7B-CD8F-4271-97B7-2DC329AA525C Q27652467-5F49E54A-AC3D-4438-AB94-CB80D3F57125 Q27653072-0D876669-8DD6-4F15-8FB9-B2ED2BF51EE7 Q27678586-0C6B1B5A-0FDF-4016-9FB6-D8424090FD6C Q27679769-0457263F-84A0-4110-B2B8-49B211BA9F5C Q27681859-B8BA3EE9-3043-4D92-9051-7C348648B205 Q28830947-C2DFCC59-3257-4583-8D20-63887F9AB8F5 Q30374663-C08D35DC-D7FB-47A4-B080-5FF6E8F64E0B Q30381368-BCA73F18-81CD-4468-856E-8FBA8BB562D6 Q30382639-9F5CAE90-F495-4A7E-AD7F-FFF8AE942689 Q33510934-D3FB9058-3DF9-480E-BDDF-A77B49A9F6A5 Q33587821-3B5DCAE4-EB26-44C9-A00F-D9862F2F6292 Q33632891-60AB9654-0752-4E5B-97CA-9F0A5CA1528C Q34002709-503FF245-C3FB-412C-9EFD-4D1E0CC6CAE5 Q34948215-E7B9C42A-177F-4463-9779-FB0B13A738DF Q35038893-2106869D-7759-4DDF-9582-3E2F6050DA9E Q35058437-FF345CA3-6AC5-4DCC-ACC7-4DBE08D27F72 Q35219426-723E0E39-E754-4CAB-B810-D43FF3EF3A7C Q35261111-D53A98D4-7764-4022-8535-384CCCB976D2 Q35653681-5A87FBBB-BB46-40C9-9CC3-7C08945316DE Q35755355-3CE7EA76-25F8-4A8F-BD5F-8DFCAE04A76D Q35763320-3DEF8327-6D51-4C57-8138-E03857DA272F Q35884666-C60E5360-2FCC-462C-AF9C-9440CC6A0903 Q35951645-111F4818-A8BD-4F87-AEA8-FC32370A436C Q35977327-B148EB3E-E6F4-4B9E-9F95-2D965BB9E96A Q36153855-9FB310AC-A770-4169-A11A-E6AB088D1003 Q36157907-847FE879-21DD-4ED5-959A-3BA8FEBDD6EF Q36375125-2DF3B0A8-0FEF-4B39-AEF9-51C14F5539B8 Q36481954-0EF73F2C-83C3-4305-9BB5-8B22FB8AA0FD Q36525474-9F682912-6393-408D-AFB5-D3C197C924EC Q36555201-65A2ED10-D0A8-4A50-BF70-4E53B9FBE8D3 Q36738608-F74F9BF2-814C-42B1-AB12-D0D4BDC5C4CF Q36822111-4463E2F0-275A-446F-832B-924C1E8D64CE Q36949808-389E83A3-2122-42B0-9203-90F3E380A73F Q36970334-D8C4FB9D-08B5-42FF-B97C-77C55F42E13D Q37135359-48888123-0DED-45CD-8088-E63EB17E33A8 Q37209222-F52A327E-31A8-4616-88B9-1125B0461E6E Q37633558-CFAF6612-C1F2-4C16-81B5-65D9D14C6A74

P2860

Structure and chemical inhibition of the RET tyrosine kinase domain

http://www.wikidata.org/entity/Q28259608

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Structure and chemical inhibition of the RET tyrosine kinase domain

@ast

Structure and chemical inhibition of the RET tyrosine kinase domain

@en

Structure and chemical inhibition of the RET tyrosine kinase domain

@nl

type

label

Structure and chemical inhibition of the RET tyrosine kinase domain

@ast

Structure and chemical inhibition of the RET tyrosine kinase domain

@en

Structure and chemical inhibition of the RET tyrosine kinase domain

@nl

prefLabel

Structure and chemical inhibition of the RET tyrosine kinase domain

@ast

Structure and chemical inhibition of the RET tyrosine kinase domain

@en

Structure and chemical inhibition of the RET tyrosine kinase domain

@nl

P1433

Q28259608-9B69092A-5D74-4220-BF3D-37DC74AEA33D

P1476

Q28259608-D651FC16-55A3-4E68-BAAA-A76F43AAE958

P2093

Q28259608-7CEC1FAA-33B2-4609-B042-162158BDA1A8

Q28259608-7DBE27D2-FCA5-4CFD-AC03-41D98D922A1F

Q28259608-9F185C83-8E5A-4E2F-AF40-AD4F5D6B98ED

Q28259608-C9CEDA3E-7B4C-4AF3-9836-9E0A476257EF

Q28259608-D8AEEF23-8316-4A4B-B6A4-E2A29FB6BCBC

Q28259608-F0B4C152-F740-485E-AE93-6702EFDDF104

P304

Q28259608-DE2E99AD-145A-420A-85C7-695CDE82EC2C

P31

Q28259608-4BDBCE04-942D-487A-8FCD-DA15D4798226

P3181

Q28259608-FB39F813-885D-4BF7-A8D6-D7BEF38A36B1

P356

Q28259608-6B96B602-ED21-49C1-86B7-33E14D43BECC

P407

Q28259608-9E482634-245C-4D4C-9F67-1D46CE8E8C4E

P433

Q28259608-BFCA6810-71BB-41F0-A43A-D581FE110D0E

P478

Q28259608-FC284F29-C195-4377-BFA9-97930861865A

P50

Q28259608-40F5E8EA-DF85-401F-A84C-2638163F4C5C

Q28259608-B4C5BB31-10B5-467D-BBA5-DD91CA5786C2

P577

Q28259608-86439122-8B73-4239-BBC9-B67966B1B227

P5875

Q28259608-4D10BCBC-8B3B-4177-A672-6E850E1CEFC2

P698

Q28259608-D276D01E-0972-42A9-9660-7B80D9E96D7E

P3181

P356

P1433

Journal of Biological Chemistry

P1476

Structure and chemical inhibition of the RET tyrosine kinase domain

@en

P2093

Carlos F Ibáñez

http://www.w3.org/2001/XMLSchema#string

Judith Murray-Rust

http://www.w3.org/2001/XMLSchema#string

Massimo Santoro

http://www.w3.org/2001/XMLSchema#string

Neil Q McDonald

http://www.w3.org/2001/XMLSchema#string

Phillip P Knowles

http://www.w3.org/2001/XMLSchema#string

Sarah Hanrahan

http://www.w3.org/2001/XMLSchema#string

P304

33577-33587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1278756

http://www.w3.org/2001/XMLSchema#string

P356

10.1074/JBC.M605604200

http://www.w3.org/2001/XMLSchema#string

P407

P433

44

http://www.w3.org/2001/XMLSchema#string

P478

281

http://www.w3.org/2001/XMLSchema#string

P50

Susanne Krüger Kjaer

Rizaldy P Scott

P577

2006-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6859000

http://www.w3.org/2001/XMLSchema#string

P698

16928683

http://www.w3.org/2001/XMLSchema#string